TY - JOUR
T1 - ACR Appropriateness Criteria® Lung Cancer Screening
T2 - 2022 Update
AU - Expert Panel on Thoracic Imaging
AU - Sandler, Kim L.
AU - Henry, Travis S.
AU - Amini, Arya
AU - Elojeimy, Saeed
AU - Kelly, Aine Marie
AU - Kuzniewski, Christopher T.
AU - Lee, Elizabeth
AU - Martin, Maria D.
AU - Morris, Michael F.
AU - Peterson, Neeraja B.
AU - Raptis, Constantine A.
AU - Silvestri, Gerard A.
AU - Sirajuddin, Arlene
AU - Tong, Betty C.
AU - Wiener, Renda Soylemez
AU - Witt, Leah J.
AU - Donnelly, Edwin F.
N1 - Funding Information:
Dr. Donnelly reports Consulting fees from Consultant for AstraZeneca. Dr. Martin reports Leadership roles as Director of Diversity and Inclusion for the Department of Radiology, University of Wisconsin School of Medicine and Public Health. Dr. Peterson reports Leadership roles as 1. Medical Director, Division of General Internal Medicine 2. Associate Program Director, Internal Medicine Residency Program 3. IRB Chair (all at Vanderbilt). Dr. Sandler reports Grants or contracts from NIH/NCI; American Cancer Society; Department of Defense; Kaiser Permanente; Consulting fees from Aidence RevealDx; Payments or honoraria from JADPRO GO2 Foundation; Payment for expert testimony from Expert witness consultation for Paganelli Law Group and Beytin, McLaughlin, McLaughlin, O'Hara & Bocchino, P.A.; Support for meetings from National Lung Cancer Roundtable; Participation on an advisory board for Medical Advisory Board member RevealDx; Leadership roles as Imaging Chair ECOG-ACRIN Thoracic Committee: Lung-RADS Committee member; Co-Chair, ACR LCS Steering Committee; NCCN LCS Panel member. Dr. Silvestri reports Grants or contracts from research - Nucleix, inc., Delfi, inc, Biodesix, inc, PrognomIQ, NCI, Stand up 2 cancer; Consulting fees from biodesix, inc;. Dr. Tong reports Consulting fees from Medtronic, Inc.; Payments or honoraria from Medtronic, Inc. Dr. Wiener reports Grants or contracts from Grants paid to my institution from the Dept of Veterans Affairs (VA HSR&D, VA QUERI, VA ORD), NIH, and PCORI.; Support for meetings from Support from the National Lung Cancer Round Table to attend their 12/2022 meeting; Participation on an advisory board for Participation in DSMB for 2 PCORI trials.; Leadership roles as paid and unpaid leadership roles in American Thoracic Society and Veterans Health Administration, unpaid leadership roles in National Lung Cancer Round Table and CHEST. Dr. Witt reports Support from salary support for academic time to participate in this project: K01HP33446-04-00 (HRSA): Geriatric Academic Career Award; Grants or contracts from K01HP33446-04-00 (HRSA): Geriatric Academic Career Award; Royalties or licenses from Royalties from textbook chapter: Current Medical Diagnosis and Treatment; Payments or honoraria from Curbsiders Internal Medicine podcast payments, Elsevier: writing Clinical Key chapter, Royalties: Current Medical Diagnosis & Treatment chapter; Support for meetings from K01HP33446-04-00 (HRSA): Geriatric Academic Career Award; Leadership roles as Pulmonary Associate Chief for Ambulatory Affairs at UCSF. Dr. Amini is a partner; and the other authors are non-partner/non-partnership track/employees.
Publisher Copyright:
© 2023 American College of Radiology
PY - 2023/5
Y1 - 2023/5
N2 - Lung cancer remains the leading cause of cancer-related mortality for men and women in the United States. Screening for lung cancer with annual low-dose CT is saving lives, and the continued implementation of lung screening can save many more. In 2015, the CMS began covering annual lung screening for those who qualified based on the original United States Preventive Services Task Force (USPSTF) lung screening criteria, which included patients 55 to 77 year of age with a 30 pack-year history of smoking, who were either currently using tobacco or who had smoked within the previous 15 years. In 2021, the USPSTF issued new screening guidelines, decreasing the age of eligibility to 80 years of age and pack-years to 20. Lung screening remains controversial for those who do not meet the updated USPSTF criteria, but who have additional risk factors for the development of lung cancer. The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed annually by a multidisciplinary expert panel. The guideline development and revision process support the systematic analysis of the medical literature from peer reviewed journals. Established methodology principles such as Grading of Recommendations Assessment, Development, and Evaluation or GRADE are adapted to evaluate the evidence. The RAND/UCLA Appropriateness Method User Manual provides the methodology to determine the appropriateness of imaging and treatment procedures for specific clinical scenarios. In those instances where peer reviewed literature is lacking or equivocal, experts may be the primary evidentiary source available to formulate a recommendation.
AB - Lung cancer remains the leading cause of cancer-related mortality for men and women in the United States. Screening for lung cancer with annual low-dose CT is saving lives, and the continued implementation of lung screening can save many more. In 2015, the CMS began covering annual lung screening for those who qualified based on the original United States Preventive Services Task Force (USPSTF) lung screening criteria, which included patients 55 to 77 year of age with a 30 pack-year history of smoking, who were either currently using tobacco or who had smoked within the previous 15 years. In 2021, the USPSTF issued new screening guidelines, decreasing the age of eligibility to 80 years of age and pack-years to 20. Lung screening remains controversial for those who do not meet the updated USPSTF criteria, but who have additional risk factors for the development of lung cancer. The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed annually by a multidisciplinary expert panel. The guideline development and revision process support the systematic analysis of the medical literature from peer reviewed journals. Established methodology principles such as Grading of Recommendations Assessment, Development, and Evaluation or GRADE are adapted to evaluate the evidence. The RAND/UCLA Appropriateness Method User Manual provides the methodology to determine the appropriateness of imaging and treatment procedures for specific clinical scenarios. In those instances where peer reviewed literature is lacking or equivocal, experts may be the primary evidentiary source available to formulate a recommendation.
KW - AUC
KW - Appropriate Use Criteria
KW - Appropriateness Criteria
KW - cancer screening
KW - chest CT
KW - lung cancer
KW - lung cancer screening
KW - screening
KW - smoking
UR - http://www.scopus.com/inward/record.url?scp=85160251720&partnerID=8YFLogxK
U2 - 10.1016/j.jacr.2023.02.014
DO - 10.1016/j.jacr.2023.02.014
M3 - Article
C2 - 37236754
AN - SCOPUS:85160251720
SN - 1546-1440
VL - 20
SP - S94-S101
JO - Journal of the American College of Radiology
JF - Journal of the American College of Radiology
IS - 5
ER -